DOCSLIB.ORG

Drugs & Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs & Therapy Volume 21, Number 10 November/December 2007 Drugs & Therapy B � U � L � L � E � T � I � N POLICIES AND PROCEDURES FORMULARY UPDATE The Pharmacy and Therapeutics Standardized dosing times Committee met October 16, 2007. 2 drugs or dosage forms were added tandard medication administration first dose. For example, a twice daily in the Formulary, and 2 dosage S times have existed for many years. injectable antibiotic order is received at forms were deleted. 3 drugs or These times are in place to improve 1400. The first dose will be scheduled for dosage forms were designated efficiency and communication. The ad- 1500. Subsequent doses will be given at nonformulary and not available. The ministration times have been modified 0300 and 1500. use of 1 drug in the Formulary was recently based on feedback received There will be a series of educational restricted. from the Departments of Nursing and sessions scheduled with the medical and Pharmacy. When dosing times are not nursing staffs to go over the more subtle specified by the prescriber, the default implications of the new policy. These ◆ ADDED times in the table (see below) will be sessions will emphasize to prescribers Cinacalcet used. that “3 times a day” is not the same as (Sensipar® by Amgen) Sodium Chloride Tablets StandardiZED DOSING TIMES (generic) Interval Standard Times ◆ DELETED Daily 0900 2 times a day (BID) 0900, 2100 Lansoprazole Delayed-Release 3 times a day (TID) 0900, 1400, 2100 Suspension 0800, 1200, 1700 (52 Psych) (Prevacid® Packets by 4 times a day (QID) 0900, 1300, 1700, 2100 TAP Pharmaceuticals)* 5 times a day 0500, 0900, 1300, 1700, 2100 Tetracycline Syrup Every 3 hours 0000, 0300, 0600, 0900, 1200, 1500, 1800, 2100 (generic)* Every 4 hours 0100, 0500, 0900, 1300, 1700, 2100 *Nonformulary and not available Every 6 hours 0600, 1200, 1800, 2400 Every 8 hours 0800, 1600, 2400 ◆ NONFORMULARY AND Every 12 hours 0900, 2100 NOT AVAILABLE Every 24 hours Time will default to hour profiled (ie, 1st order processed) Lubiprostone Bedtime 2100 (Amitiza® by Takeda With meals 0800, 1200, 1700 Pharmaceuticals) With meals and at bedtime 0800, 1200, 1700, 2100 Injectable antibiotics Times determined by the time the 1st dose is processed ◆ CRITERIA-FOR-USE CHANGES Corticotropin Repository There are several medications that “every 8 hours.” For oral drugs, every- Injection (Acthar® Gel by have unique specified dosing times: to 8-hour dosing requires that patients be Questor Pharmaceuticals)† allow laboratory values to be evaluated awakened to receive their dose. Waking †Restricted to approval by Pediatric before the dose is given (ie, warfarin , the patient may or may not be neces- Neurology for infantile spasms epoetin, darbepoetin, and filgrastim at sary, depending on the medication. 1800); to avoid meals (ie, oral fluoro- For more information on standardized quinolones at 0600 and 1600 [meals dosing times or to schedule an inservice Cinacalcet was evaluated for are generally given at 0800, 1200, and on this topic, contact Dr. Erin Jones in possible addition in the Formulary 1700]); convention (ie, cyclosporine at the Department of Pharmacy Services at because of high-volume nonformu- 0800 and 2000); for patient convenience 265-0404. lary use. Cinacalcet is an oral calci- (ie, furosemide at 0900 and 1800); and, mimetic agent that was approved to improve efficacy (ie, statins at bed- by the FDA in March 2004. It is the ◆ time). only agent in its therapeutic class. Because injectable antibiotics should INSIDE THIS ISSUE Cinacalcet has labeled indications be started as soon as possible and for use in the treatment of second- ◆ prolonged intervals could affect efficacy, Medical foods? ary hyperparathyroidism in patients the dosage time for injectable antibiot- ◆ Annual index (continued on next page) ics will be determined by the time of the Formulary update, from page 1 The new enteral feeding system used has an FDA-labeled indication for the with chronic kidney disease on dialysis by Dietary Services does not allow the treatment of chronic idiopathic consti- and for the treatment of hypercalcemia addition of specific electrolytes. Extra pation. The labeled dose is 1 capsule in patients with parathyroid carcinoma. sodium chloride must be administered (24 mcg) twice daily with meals. The Chronic kidney disease is associated separately. This is usually done using drug has not been specifically stud- with hyperphosphatemia, hypocalce- sodium chloride 4 mEq/mL injection in ied in patients with hepatic or renal mia, and increased stimulation of the an oral syringe. However, adult and impairment, but the need for dos- parathyroid gland. These alterations older pediatric patients who can take age adjustments is unlikely as it has lead to secondary hyperparathyroid- oral solids can be supplemented with minimal systemic availability. Safety ism, a progressive condition that 1-gram sodium chloride tablets (ie, de- and efficacy have not been established eventually results in bone disease livering 17.2 mEq of sodium per tablet). in children or adolescents. A lower and calcification of vascular and soft Prevacid® for Delayed-Release Oral strength of lubiprostone (ie, 8 mcg) to tissues. Suspension Packets will no longer be treat irritable bowel syndrome with Cinacalcet acts on the calcium- marketed by TAP Pharmaceuticals. This constipation is currently under review sensing receptor on the surface of the product is not used much; other dosage by the FDA. chief cell in the parathyroid gland. The forms are more popular. The packets There are no head-to-head studies calcium-sensing receptor is the princi- were deleted from the Formulary and comparing lubiprostone to other agents pal regulator of parathyroid hormone designated nonformulary and not avail- used to treat chronic constipation (ie, (PTH) secretion. By mimicking calcium, able. bulk-forming fiber products or stool cinacalcet increases the sensitivity of Lansoprazole suspension compound- softeners). The approval of lubipros- the calcium-sensing receptor to extra- ed using sodium bicarbonate is a better tone was primarily based on 2 random- cellular calcium and lowers PTH levels. alternative for administering lansopra- ized, double-blind, placebo-controlled, Decreased serum calcium is associated zole down a feeding tube. Prevacid® phase 3 trials that showed moder- with reduction in PTH. After 1 week of Oral Suspension Packets produced a ate improvements in weekly bowel therapy, reduction in serum calcium is thick suspension because it contained movements (ie, an absolute increase seen and maintained. xanthan gum to increase viscosity. This of approximately 2 bowel movements Managing patients, according to the thick suspension often clogged feeding per week [approximately 3 vs 5]). Also, National Kidney Foundation’s Kidney tubes, especially small-bore feeding only approximately 60% of patients Disease Outcomes Quality Initiative (K/ tubes. had a spontaneous bowel movement in DOQI) guidelines on bone metabolism Prevacid® SoluTabs® have a pleas- the first 24 hours of treatment. and disease in chronic kidney disease, ant taste and can be used to administer The most commonly reported ad- can be challenging. Traditional thera- lansoprazole orally in small children who verse effect during clinical trials was pies for stage 5 chronic kidney disease cannot swallow capsules. The SoluTabs® nausea. The incidence of nausea is include phosphate-binders and vitamin can also be dissolved in a small amount dose-related; 8% of patients discontin- D sterols and can be associated with of water and administered down a feed- ued treatment during trials due to nau- hypercalcemia. ing tube. The granules in the SoluTabs® sea. Other common side effects during Evidence from randomized, placebo- do not clump or stick to the feeding tube. trials included diarrhea, headache, and controlled trials in dialysis patients Tetracycline syrup has been discon- abdominal pain or distension. shows that cinacalcet is effective in tinued by its manufacturer. There is no Chronic constipation is primarily reducing intact PTH while also reduc- alternative source. After consulting with treated on an outpatient basis. There ing serum calcium, phosphorus, and the Infectious Diseases Subcommittee, are various low-cost formulary op- calcium-phosphorus product. At the there appears to be no need to recom- tions available for acute treatment of start of these studies, patients had mend an alternative agent. Tetracycline constipation (eg, senna), as well as elevated PTH in spite of treatment syrup was designated nonformulary and fiber products and stool softeners for with phosphate binders and/or vitamin not available. possible prevention. Patients admit- D sterols. At this time, a large prospec- Lubiprostone was evaluated for pos- ted who are already taking lubipros- tive, randomized, placebo-controlled sible addition in the Formulary based on tone may take their own supply or be trial is being conducted to determine if requests for use and potential for inap- treated with other formulary agents cinacalcet reduces the risk of mortality propriate off-label use. for constipation during hospitaliza- or cardiovascular events in hemodialy- Lubiprostone is a member of a new tion. Additionally, discontinuation sis patients. class of bicyclic fatty acids prostaglan- of lubiprostone does not result in a The most common adverse events din E1 derivatives known as prostones. rebound effect and, in fact, shows a associated with cinacalcet use are It increases intestinal fluid secretion via sustained
Load more

Recommended publications
  • A1.5 Morphine A6 ATC Code: N02AA01 Oral Liquid: 2 Mg (As Hydrochloride Or Sulfate)/Ml
    A1 A2 A3 A4 A5 A1.5 Morphine A6 ATC code: N02AA01 Oral liquid: 2 mg (as hydrochloride or sulfate)/ml. Tablet: 10 mg (as sulfate). Tablet (prolonged release): 10 mg, 30 mg, 60 mg, 100 mg, 200 mg (as sulfate). Granules: (prolonged release, to mix with water): 20 mg, 30 mg, 60 mg, 100 mg, 200 mg (morphine sulfate). Injection: 10 mg (as hydrochloride or sulfate) in 1 ml ampoule. A7 Indications: moderate to severe persisting pain. 73 < Contraindications: hypersensitivity to opioid agonists or to any component of the formulation; acute respiratory depression; acute asthma; paralytic ileus; concomitant use of, or use within 14 days after ending monoamine oxidase inhibitors; raised intracranial pressure and/or head injury, if ventilation not controlled; coma; use within 24 hours before or after surgery. Precautions: impaired respiratory function; avoid rapid injection which may precipitate chest wall rigidity and difficulty with ventilation; bradycardia; asthma; hypotension; shock; obstructive or inflammatory bowel disorders; biliary tract disease; convulsive disorders; hypothyroidism; adrenocortical insufficiency; avoid abrupt withdrawal after prolonged treatment; diabetes mellitus; impaired consciousness; acute pancreatitis; myasthenia gravis; hepatic impairment; renal impairment; toxic psychosis. Skilled tasks: warn the patient or carer about the risk of undertaking tasks requiring attention or coordination, for example, riding a bike. Dosage: Starting dose for opioid-naive patients: Oral (immediate-release formulation): • infant 1–12 months – 80–200 mcg/kg every 4 hours; • child 1–2 years – 200–400 mcg/kg every 4 hours; • child 2–12 years – 200–500 mcg/kg every 4 hours; maximum oral starting dose is 5 mg. Oral (prolonged-release formulation): • child 1–12 years – initially 200–800 mcg/kg every 12 hours.
    [Show full text]
  • SAMHSA Opioid Overdose Prevention TOOLKIT
    SAMHSA Opioid Overdose Prevention TOOLKIT Opioid Use Disorder Facts Five Essential Steps for First Responders Information for Prescribers Safety Advice for Patients & Family Members Recovering From Opioid Overdose TABLE OF CONTENTS SAMHSA Opioid Overdose Prevention Toolkit Opioid Use Disorder Facts.................................................................................................................. 1 Scope of the Problem....................................................................................................................... 1 Strategies to Prevent Overdose Deaths.......................................................................................... 2 Resources for Communities............................................................................................................. 4 Five Essential Steps for First Responders ........................................................................................ 5 Step 1: Evaluate for Signs of Opioid Overdose ................................................................................ 5 Step 2: Call 911 for Help .................................................................................................................. 5 Step 3: Administer Naloxone ............................................................................................................ 6 Step 4: Support the Person’s Breathing ........................................................................................... 7 Step 5: Monitor the Person’s Response ..........................................................................................
    [Show full text]
  • Method of Rough Estimation of Median Lethal Dose (Ld50)
    b Meta olis g m & ru D T o f x o i Journal of Drug Metabolism and l c a o n l o r Saganuwan, J Drug Metab Toxicol 2015, 6:3 g u y o J Toxicology DOI: 10.4172/2157-7609.1000180 ISSN: 2157-7609 Research Article Open Access Arithmetic-Geometric-Harmonic (AGH) Method of Rough Estimation of Median Lethal Dose (Ld50) Using Up – and – Down Procedure *Saganuwan Alhaji Saganuwan Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria *Corresponding author: Saganuwan Alhaji Saganuwan, Department of Veterinary Physiology, Pharmacology and Biochemistry, College Of Veterinary Medicine, University Of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria, Tel: +2348027444269; E-mail: [email protected] Received date: April 6,2015; Accepted date: April 29,2015; Published date: May 6,2015 Copyright: © 2015 Saganuwan SA . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Earlier methods adopted for the estimation of median lethal dose (LD50) used many animals (40 – 100). But for the up – and – down procedure, 5 – 15 animals can be used, the number I still consider high. So this paper seeks to adopt arithmetic, geometric and harmonic (AGH) mean for rough estimation of median lethal dose (LD50) using up – and – down procedure by using 2 – 6 animals that may likely give 1 – 3 reversals. The administrated doses should be summed up and the mean, standard deviation (STD) and standard error of mean (SEM) should be determined.
    [Show full text]
  • Medication Administration
    MEDICATION ADMINISTRATION GENERAL CONSIDERATIONS A. Before administering any medication, the EMT should know: 1. What is the medication being used? 2. Does the patient have an allergy to this medication? 3. What is the safe and effective dose? 4. What is the correct administration route? 5. What are the indications? (Why are you using is?) 6. What are the contraindications? (Why or when would you NOT use this medication?) 7. What are the expected effects? 8. What are the adverse effects / side effects? 9. Is the medication expired? B. The “Six Rights” of medication administration: 1. Right patient – is the medication indicated for this patient; no contraindications; no allergies 2. Right drug – the correct name (trade name vs. generic name); correct concentration 3. Right dose 4. Right route 5. Right time – slow IVP vs. rapid IVP 6. Right documentation C. Correct documentation of medications administered and/or IV/IO placement will include: 1. Time of medication administration; IV/IO placement 2. Route of administration 3. Size of catheter (IV/IO) 4. Site location for IV/IO and SQ, IM medication (include unsuccessful IV/IO attempt locations) 5. Dose or volume infused 6. Time of infusion as indicated (e.g., rapid IVP, infused over 10 minutes, etc.) 7. Name of EMT responsible 8. Any complications and steps made to correct 9. Patient’s response to treatment D. Use of a medication simply because it is in the protocol is not an acceptable standard of medical care. When there are questions about medication administration, consult medical control. ORAL ADMINSTRATION To administer an oral (PO) medication ensure that the patient has an intact gag reflex and place the patient in a seated or semi-seated position.
    [Show full text]
  • Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents
    OECD/OCDE 408 Adopted: 25 June 2018 │ OECD GUIDELINE FOR THE TESTING OF CHEMICALS Repeated dose 90-day oral toxicity study in rodents INTRODUCTION 1. OECD Guidelines for the Testing of Chemicals are periodically reviewed in the light of scientific progress, changing regulatory needs, and animal welfare considerations. The original guideline 408 was adopted in 1981. In 1998 a revised version was adopted, to obtain additional information from the animals used in the study, based on the outcome of an OECD Consultation Meeting of Experts on Sub- chronic and Chronic Toxicity Testing held in Rome in 1995 (1). 2. This Test Guideline (TG) was updated in 2018 to add endocrine-sensitive endpoints intended to improve detection of potential endocrine activity of test chemicals and mirrors updates to TG 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents). INITIAL CONSIDERATIONS 3. In the assessment and evaluation of the toxic characteristics of a chemical, the determination of sub-chronic oral toxicity using repeated doses may be carried out after initial information on toxicity has been obtained from acute or repeated dose 28-day toxicity tests. The 90- day study provides information on the possible health hazards likely to arise from repeated exposure over a prolonged period of time covering post-weaning maturation and growth into adulthood of the test animals. The study will provide information on the major toxic effects, indicate target organs and the possibility of accumulation of test chemical, and can provide an estimate of a no-observed-adverse-effect level (NOAEL) of exposure which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure.
    [Show full text]
  • Young Medication Dose Calcul
    Nurse Education in Practice 13 (2013) e11ee22 Contents lists available at SciVerse ScienceDirect Nurse Education in Practice journal homepage: www.elsevier.com/nepr Safety in numbers 1: Essential numerical and scientific principles underpinning medication dose calculation Simon Young a, Keith W. Weeks a,*, B. Meriel Hutton b a Faculty of Health, Sport & Science, University of Glamorgan, UK b King’s College London, UK article info abstract Article history: Registered nurses spend up to 40% of their professional clinical practice engaged in the art and science of Accepted 17 October 2012 medication dosage calculation problem-solving (MDC-PS). In advancing this patient safety critical discipline it is our position that as a profession we must first situate MDC-PS within the context of the Keywords: wider features of the nursing numeracy, medicines management and clinical pharmacokinetic domains Medicines dosage calculations that inform its practice. This paper focuses on the essential relationship between numeracy, healthcare Healthcare numeracy numeracy, medicines management, pharmacokinetics and MDC-PS. We present a taxonomy of generic Fundamental clinical pharmacokinetics numerical competencies for the pre-registration curriculum, with examples of essential medication dosage calculation requirements mapped to each skills domain. This is followed by a review of the symbols and measurement units that represent essential components of calculation competence in healthcare and medicines management practice. Finally we outline the fundamental pharmacokinetic knowledge that explains how the body deals with medication and we illustrate through clinical corre- lations why numeric and scientific knowledge and skills must be mastered to ensure safe dosage calculation and medicines management practice. The findings inform nurse education practice via advancing our understanding of a number of issues, including a unified taxonomy of generic numerical competencies mapped to the 42 revised UK Nursing and Midwifery Council (NMC) Essential Skills Clusters (NMC, 2010a; NMC, 2010b).
    [Show full text]
  • Psychoactive Prescription Drug Use Disorders, Misuse and Abuse Pharmacoepidemiological Aspects
    Psychoactive prescription drug use disorders, misuse and abuse Pharmacoepidemiological aspects Micaela Tjäderborn Division of Drug Research Institution of Medical and Health Sciences Linköping University Linköping, Sweden 2016 Psychoactive prescription drug use disorders, misuse and abuse © Micaela Tjäderborn 2016 [email protected] ISBN: 978-91-7685-770-0 ISSN: 0345-0082 Printed in Linköping, Sweden 2016 Liu-Tryck AB ii All the passionate work I put into this thesis is dedicated to my parents, who always emphasized the importance of knowledge and of caring for the less fortunate. iii iv Psychoactive prescription drug use disorders, misuse and abuse Pharmacoepidemiological aspects Micaela Tjäderborn Division of Drug Research Institution of Medical and Health Sciences Linköping University, Linköping, Sweden Background: There is a widespread and increasing use of psychoactive prescription drugs, such as opioid analgesics, anxiolytics, hypnotics and anti-epileptics, but their use is associated with a risk of drug use disorder, misuse and abuse. Today, these are globally recognised and emerging public health concerns. Aim: The aim of this thesis is to estimate the occurrence and prevalence of psychoactive prescription drug use disorders, misuse and abuse, and to investigate the association with some potential risk factors. Methods: A study using register data from forensic cause of death investigations analysed and described cases of fatal unintentional intoxications with tramadol (Study I). Based on register data on spontaneously reported adverse drug reactions (ADRs) reported cases of tramadol dependence were scrutinized and summarised (Study II). In a study in suspected drug-impaired drivers with a toxicology analysis confirming intake of tramadol, diazepam, flunitrazepam, zolpidem and zopiclone, the prevalence of non-prescribed use was assessed and associated factors were investigated (Study III).
    [Show full text]
  • 1. Administering Vaccines: Dose, Route, Site, and Needle Size
    Administering Vaccines: Dose, Route, Site, and Needle Size Vaccine Dose Route Injection Site and Needle Size Pfizer-BioNTech Subcutaneous (Subcut) injection ≥12 yrs: 0.3 mL COVID-19 IM . Use a 23–25 gauge needle. Choose the injection site that is appropriate to Moderna; Janssen the person’s age and body mass. ≥18 yrs: 0.5 mL Needle Diphtheria, Tetanus, Pertussis age injection site 0.5 mL. IM .. length (DTaP, DT, Tdap, Td) Fatty tissue over anterolateral Infants (1–12 mos) ⅝" Haemophilus influenzae type b (Hib) 0.5 mL IM thigh muscle ≤18 yrs: 0.5 mL Fatty tissue over anterolateral Hepatitis A (HepA) IM Children 12 mos or older, ⅝" thigh muscle or fatty tissue ≥19 yrs: 1.0 mL adolescents, and adults over triceps Engerix-B; Recombivax HB Hepatitis B (HepB) ≤19 yrs: 0.5 mL Intramuscular (IM) injection Persons 11–15 yrs may be given Recombivax HB (Merck) ≥20 yrs: 1.0 mL IM Use a 22–25 gauge needle. Choose the injection site and needle length that 1.0 mL adult formulation on a 2-dose schedule. Heplisav-B is appropriate to the person’s age and body mass. ≥18 yrs: 0.5 mL needle Human papillomavirus (HPV) 0.5 mL IM age length injection site 0.2 mL (0.1 mL in Intranasal 1 Influenza, live attenuated (LAIV) Newborns (1st 28 days) ⅝" Anterolateral thigh muscle each nostril) spray Infants (1–12 mos) 1" Anterolateral thigh muscle Afluria: 0.25 mL 1–1¼" Anterolateral thigh muscle2 Influenza, inactivated (IIV); for ages Fluzone: 0.25 or 0.5 mL Toddlers (1–2 years) IM 1 6–35 months ⅝–1" Deltoid muscle of arm FluLaval; Fluarix: 0.5 mL Children ⅝–1"1 Deltoid
    [Show full text]
  • RADIOPHARMACEUTICALS Final Text for Addition to the International Pharmacopoeia (November 2008)
    Document QAS/08.262/FINAL November 2008 RADIOPHARMACEUTICALS Final text for addition to The International Pharmacopoeia (November 2008) This text was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 for addition to the 4 th edition of The International Pharmacopoeia . Contents Introduction Monographs General monograph Specific monographs Methods of Analysis Supplementary Information Introduction Radiopharmaceuticals are unique medicinal formulations containing radioisotopes which are used in major clinical areas for diagnosis and/or therapy. The facilities and procedures for the production, use, and storage of radiopharmaceuticals are subject to licensing by national and/or regional authorities. This licensing includes compliance both with regulations governing pharmaceutical preparations and with those governing radioactive materials. Additional regulations may apply for issues such as transportation or dispensing of radiopharmaceuticals. Each producer or user must be thoroughly cognizant of the national requirements pertaining to the articles concerned. Regulations concerning pharmaceutical preparations include the application of current Good Manufacturing Practices (GMP). Guidelines are available in Quality assurance of pharmaceuticals, Volume 2: Good manufacturing Document QAS/08.262/FINAL page 2 practices and inspection (WHO, Geneva, 2004); for the current WHO recommendations consult the WHO Medicines web site (http://www.who.int/medicines). Regulations governing radioactive materials include those on safe handling and production of radioisotopes. See International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources (IAEA, Vienna, 2003, CD-ROM Edition) Safety Series No. 115/CD and Radiological Protection for Medical Exposure to Ionizing Radiation Safety Guide (IAEA, Vienna, 2002) Safety Standard Series No.
    [Show full text]
  • E 4: Dose Response Information to Support Drug Registration
    European Medicines Agency November 1994 CPMP/ICH/378/95 ICH Topic E 4 Dose Response Information to Support Drug Registration Step 5 NOTE FOR GUIDANCE ON DOSE RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION (CPMP/ICH/378/95) APPROVAL BY CPMP May 1994 DATE FOR COMING INTO OPERATION November 1994 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: [email protected] http://www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged DOSE-RESPONSE INFORMATION TO SUPPORT DRUG REGISTRATION ICH Harmonised Tripartite Guideline 1. INTRODUCTION Purpose of Dose-Response Information Knowledge of the relationships among dose, drug-concentration in blood, and clinical response (effectiveness and undesirable effects) is important for the safe and effective use of drugs in individual patients. This information can help identify an appropriate starting dose, the best way to adjust dosage to the needs of a particular patient, and a dose beyond which increases would be unlikely to provide added benefit or would produce unacceptable side effects. Dose-concentration, concentration- and/or dose-response information is used to prepare dosage and administration instructions in product labeling. In addition, knowledge of dose-response may provide an economical approach to global drug development, by enabling multiple regulatory agencies to make approval decisions from a common database. Historically, drugs have often been initially marketed at what were later recognized as excessive doses (i.e., doses well onto the plateau of the dose-response curve for the desired effect), sometimes with adverse consequences (e.g.
    [Show full text]
  • Guidance for Industry
    Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2010 Labeling Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 (Tel) 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2010 Labeling Contains Nonbinding Recommendations 1 2 TABLE OF CONTENTS 3 4 I. INTRODUCTION............................................................................................................. 1 5 II. DOSAGE AND ADMINISTRATION SECTION — CONTENT...............................
    [Show full text]
  • Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials
    Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) January 2010 ICH Revision 1 Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Additional copies are available from: Office of Communications Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave. Bldg. 51, Room 2201 Silver Spring, MD 20993-0002 (Tel) 301-796-3400 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 (Tel) 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Drug Evaluation and Research (CBER) January 2010 ICH Revision 1 Contains Nonbinding Recommendations TABLE OF CONTENTS List of Abbreviations I. INTRODUCTION (1)....................................................................................................... 1 A. Objectives
    [Show full text]